- Home
- CCCC vs TLSI Comparison
CCCC vs TLSI Comparison
Compare CCCC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- TLSI
- Stock Information
- Founded
- CCCC 2015
- TLSI 2010
- Country
- CCCC United States
- TLSI United States
- Employees
- CCCC N/A
- TLSI N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- CCCC Health Care
- TLSI Health Care
- Exchange
- CCCC Nasdaq
- TLSI Nasdaq
- Market Cap
- CCCC 175.1M
- TLSI 150.0M
- IPO Year
- CCCC 2020
- TLSI N/A
- Fundamental
- Price
- CCCC $2.71
- TLSI $4.89
- Analyst Decision
- CCCC Buy
- TLSI Strong Buy
- Analyst Count
- CCCC 3
- TLSI 5
- Target Price
- CCCC $8.00
- TLSI $10.90
- AVG Volume (30 Days)
- CCCC 1.2M
- TLSI 109.8K
- Earning Date
- CCCC 10-30-2025
- TLSI 08-12-2025
- Dividend Yield
- CCCC N/A
- TLSI N/A
- EPS Growth
- CCCC N/A
- TLSI N/A
- EPS
- CCCC N/A
- TLSI N/A
- Revenue
- CCCC $34,240,000.00
- TLSI $35,990,000.00
- Revenue This Year
- CCCC N/A
- TLSI $56.79
- Revenue Next Year
- CCCC N/A
- TLSI $54.15
- P/E Ratio
- CCCC N/A
- TLSI N/A
- Revenue Growth
- CCCC 16.55
- TLSI 45.50
- 52 Week Low
- CCCC $1.09
- TLSI $3.42
- 52 Week High
- CCCC $7.22
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- CCCC 60.68
- TLSI 51.95
- Support Level
- CCCC $2.57
- TLSI $4.80
- Resistance Level
- CCCC $2.85
- TLSI $5.24
- Average True Range (ATR)
- CCCC 0.19
- TLSI 0.31
- MACD
- CCCC -0.01
- TLSI 0.00
- Stochastic Oscillator
- CCCC 72.88
- TLSI 49.26
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.